Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2007-04-23
2011-11-01
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S311000, C514S314000, C514S355000, C514S357000, C514S365000, C514S367000, C514S471000, C514S599000, C514S601000, C514S602000, C514S605000, C514S466000, C544S335000, C546S169000, C546S316000, C546S335000, C546S336000, C548S164000, C548S204000, C549S065000, C549S438000, C549S501000
Reissue Patent
active
RE042889
ABSTRACT:
α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
REFERENCES:
patent: 4450164 (1984-05-01), Bristol et al.
patent: 4477441 (1984-10-01), Boger et al.
patent: 4514391 (1985-04-01), Gordon et al.
patent: 4548926 (1985-10-01), Matsueda et al.
patent: 4599198 (1986-07-01), Hoover
patent: 4616088 (1986-10-01), Ryono et al.
patent: 4668769 (1987-05-01), Hoover
patent: 4668770 (1987-05-01), Boger et al.
patent: 4757050 (1988-07-01), Natarajan et al.
patent: 4757060 (1988-07-01), Lukacsko et al.
patent: 4826815 (1989-05-01), Luly et al.
patent: 4880938 (1989-11-01), Freidinger
patent: H725 (1990-01-01), Gordon
patent: 4963530 (1990-10-01), Hemmi et al.
patent: 4977277 (1990-12-01), Rosenberg et al.
patent: 5122514 (1992-06-01), Boger et al.
patent: 5134123 (1992-07-01), Branca et al.
patent: 5140011 (1992-08-01), Branca et al.
patent: 5194608 (1993-03-01), Toyoda et al.
patent: 5215967 (1993-06-01), Gante et al.
patent: 5223615 (1993-06-01), Toyoda et al.
patent: 5272268 (1993-12-01), Toyoda et al.
patent: 5278148 (1994-01-01), Branca et al.
patent: 5463104 (1995-10-01), Vazquez et al.
patent: 5475013 (1995-12-01), Talley et al.
patent: 5514801 (1996-05-01), Bertenshaw et al.
patent: 5521219 (1996-05-01), Vazquez et al.
patent: 5532215 (1996-07-01), Lezdey et al.
patent: 5541206 (1996-07-01), Kempf et al.
patent: 5552558 (1996-09-01), Kempf et al.
patent: 5585397 (1996-12-01), Tung et al.
patent: H1649 (1997-05-01), Barrish et al.
patent: 5674882 (1997-10-01), Kempf et al.
patent: 5691372 (1997-11-01), Tung et al.
patent: 5723490 (1998-03-01), Tung
patent: 5744481 (1998-04-01), Vazquez et al.
patent: 5786483 (1998-07-01), Vazquez et al.
patent: 5830897 (1998-11-01), Vazquez et al.
patent: 5843946 (1998-12-01), Vazquez et al.
patent: 5856353 (1999-01-01), Tung et al.
patent: 5968942 (1999-10-01), Vazquez et al.
patent: 5977137 (1999-11-01), Tung et al.
patent: 6004927 (1999-12-01), Benet et al.
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6046190 (2000-04-01), Vazquez et al.
patent: 6054490 (2000-04-01), Sime et al.
patent: 6060476 (2000-05-01), Vazquez et al.
patent: 6100277 (2000-08-01), Tucker et al.
patent: 6172082 (2001-01-01), Vazquez et al.
patent: 6177466 (2001-01-01), Sakaki et al.
patent: 6191165 (2001-02-01), Ognyanov et al.
patent: 6211176 (2001-04-01), Vazquez et al.
patent: 6245809 (2001-06-01), Scarborough et al.
patent: 6248775 (2001-06-01), Vazquez et al.
patent: 6251874 (2001-06-01), Lisziewicz et al.
patent: 6313345 (2001-11-01), Vazquez et al.
patent: 6335460 (2002-01-01), Vazquez et al.
patent: 6417387 (2002-07-01), Vazquez et al.
patent: 6455581 (2002-09-01), Vazquez et al.
patent: 6472407 (2002-10-01), Vazquez et al.
patent: 6500832 (2002-12-01), Vazquez et al.
patent: 6534493 (2003-03-01), Vazquez et al.
patent: 6646010 (2003-11-01), Vazquez et al.
patent: 6846954 (2005-01-01), Vazquez et al.
patent: 6869925 (2005-03-01), Eisenberg et al.
patent: 6890942 (2005-05-01), Walker et al.
patent: 6924286 (2005-08-01), Vazquez et al.
patent: 6943170 (2005-09-01), Carini
patent: 6958331 (2005-10-01), Brain et al.
patent: 7026333 (2006-04-01), Mueller et al.
patent: 7112683 (2006-09-01), Bertenshaw et al.
patent: 7115618 (2006-10-01), Vazquez et al.
patent: 7141609 (2006-11-01), Vazquez et al.
patent: 7320983 (2008-01-01), Vazquez et al.
patent: 7531538 (2009-05-01), Vazquez et al.
patent: 7829564 (2010-11-01), Vazquez et al.
patent: A-79823/87 (1988-04-01), None
patent: 2045008 (1991-12-01), None
patent: 2352452 (1975-04-01), None
patent: 3635907 (1988-04-01), None
patent: 0 104 041 (1984-03-01), None
patent: 0 114 993 (1984-06-01), None
patent: 0 172 347 (1986-02-01), None
patent: 0 223 437 (1987-05-01), None
patent: 0 264 795 (1988-04-01), None
patent: 0 337 714 (1989-10-01), None
patent: 0 342 541 (1989-11-01), None
patent: 0 346 847 (1989-12-01), None
patent: 356223 (1990-02-01), None
patent: 389898 (1990-10-01), None
patent: 389898 (1990-10-01), None
patent: 393445 (1990-10-01), None
patent: 393457 (1990-10-01), None
patent: 402646 (1990-12-01), None
patent: 0434365 (1991-06-01), None
patent: 468641 (1992-01-01), None
patent: WO94/05639 (1994-03-01), None
patent: 2184730 (1957-07-01), None
patent: 1435386 (1976-05-01), None
patent: 2184730 (1987-07-01), None
patent: 2200115 (1988-07-01), None
patent: 2209752 (1989-05-01), None
patent: 50041814 (1975-04-01), None
patent: A-79823/87 (1984-08-01), None
patent: WO 84/03044 (1984-08-01), None
patent: WO 86/06726 (1986-11-01), None
patent: WO 92/00750 (1992-01-01), None
patent: WO 92/08688 (1992-05-01), None
patent: WO 92/08701 (1992-05-01), None
patent: WO 93/08184 (1993-04-01), None
patent: WO 93/09096 (1993-05-01), None
patent: WO 93/23388 (1993-11-01), None
patent: WO-94/04492 (1994-03-01), None
patent: WO 94/05300 (1994-03-01), None
patent: WO 94/05639 (1994-03-01), None
patent: WO 94/26749 (1994-11-01), None
patent: WO 95/06030 (1995-03-01), None
patent: WO 95/09843 (1995-04-01), None
patent: WO 97/01349 (1997-01-01), None
patent: WO 99/33792 (1999-07-01), None
patent: WO 99/67417 (1999-12-01), None
Ghosh et al., “Structured-Based Design of HIV-1 Proteinase Inhibitors: Replacement of Two amides and a 10π-Aromatic System by a Fused Bis-tetrahydrofuran”,J. Med. Chem.37, pp. 2506-2508 (1994).
Roberts, et al., “Rational Design of Peptide-based Proteinase Inhibitors,” Science, vol. 248, p. 358 (1990).
Erickson, et al., “Design Activity, and 2.BA Crystal Structure of a C2Symmetric Inhibitor Complexed to HIV-1 Protease,” Science, vol. 249, p. 527 (1990).
Pearl, et al., “Sequence specificity of retroviral proteases,” Nature, 328, (1987).
Martin, “Drugs of the Future, 16” vol. 3, pp. 210-212 (1991).
Meek, et al., “Letter to Nature,” vol. 343, pp. 90-92 (1990).
Rosenberg, et al., J. Med. Chem., vol. 30, pp. 1224-1228 (1987).
U.S. Appl. No. 08/061,897, filed May 14, 1993, Merck & Co., Inc.
U.S. Appl. No. 08/485,524, filed Jun. 7, 1995, Vazquez et al.
U.S. Appl. No. 07/934,984, filed Aug. 25, 1992, Vazquez et al.
Barry et al., “Protease Inhibitors in Patients with HIV Disease”, Clinical Pharma., 1997, 32(3), 194-209.
Darke et al., “Human Immunodeficiency Virus Protease”, The Journal of Biological Chemistry, 1989, 264(4), 2307-2312.
Ghosh et al., “3-Tetrahydrofuran and Pyran Urethanes as High-Affinity P2-Ligands for HIV-1 Protease Inhibitors”, Journal of Medicinal Chemistry., 1993, 36(2), 292-294.
Merry et al., “Saquinavir Pharmacokinetics Alone and in Combination with Ritonavir in HIV-Infected Patients”, AIDS, 1997 11(4), F29-F33.
Toyoda et al., “Preparation of Dipeptide Renin Inhibitors”, Jan. 29, 1992, CA117:449265.
Yun et al. “Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of Cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation,” Drug Metabol. And Dispos. 21(3):403-409, 1993.
Lewis et al “Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes,” Cancer Res. 52:4379-4384, 1992.
Le Blanc et al. “Interaction of anticancer drugs with hepatic monooxygenase enzymes,” Drug Metab. Rev. 20:395-439, 1989.
Robins et al. “HIV Protease Inhibitors: Their Anti-HIV Activity and Potential Role in Treatment,” J. of Acquired Immune Deficiency Syndromes 6:162-170, 1993.
Wlodawer et al. “Structure-based inhibitors of HIV-1 Protease,” Annual Review of Biochemistry, 62:543-585, 1993.
Fittkau, J. Prakt. Chem. 1973, 315, 1037-1044 (No English translation available).
Pauwels et al., “Rapid and Automated Tetrazolium-based Colorimetric Assay for the Detection of Anti-HIV Compounds”, J. Virol. Methods, 1988, 20, 309-321.
Hetero Drugs Ltd., “Certificate of Non-Infringement and/or Invalidity of United States Patent Nos. 5,843,946; 6,037,157; 6,248,775; 6,335,460;
Bertenshaw Deborah E.
DeCrescenzo Gary A.
Freskos John N.
Getman Daniel P.
Heintz Robert M.
Connolly Bove & Lodge & Hutz LLP
G.D. Searle LLC
Saeed Kamal
LandOfFree
α- and β- amino acid hydroxyethylamino... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with α- and β- amino acid hydroxyethylamino..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and α- and β- amino acid hydroxyethylamino... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272892